EXACT Therapeutics receives regulatory approval to start the dose expansion part of ACTIVATE study 

Written By John M. Edminson

EXACT THERAPEUTICS AS (“EXACT-Tx”, Euronext Growth: EXTX), a clinical stage precision health company utilising Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, today announces that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has awarded all necessary approvals to start the dose expansion part of the ACTIVATE study.  

 This part of the ACTIVATE study is designed to determine the dose level for further development and expand the safety and efficacy data of ACT in patients with metastatic colorectal cancer. 12 to 20 patients are planned to be enrolled into the dose expansion part of the ACTIVATE study.  

 For more information, please contact:  

Per Walday  

CEO EXACT Therapeutics  

Email: per.walday@exact-tx.com  

John M. Edminson
Previous

EXACT Therapeutics completed the dose escalation part of ACTIVATE study
Next

ICR London and EXACT Therapeutics in collaborating project